Mosquirix (RTS,S): Vaccine to Prevent Plasmodium falciparum
Development of a vaccine for malaria is a medical breakthrough that has potential to prevent significant disease worldwide. Mosquirix (RTS,S) has demonstrated efficacy and safety in Phase 1 and 2 trials and recent Phase 3 trials. The major challenges that need to be addressed include determination of duration of immunity, assessment of vaccine cost-effectiveness, its use in special populations, and its dissemination in endemic regions. Pending further results from Phase 3 trials, Mosquirix has the potential to become the benchmark as the first vaccine against malaria that is highly effective and safe.
Summary
Development of a vaccine for malaria is a medical breakthrough that has potential to prevent significant disease worldwide. Mosquirix (RTS,S) has demonstrated efficacy and safety in Phase 1 and 2 trials and recent Phase 3 trials. The major challenges that need to be addressed include determination of duration of immunity, assessment of vaccine cost-effectiveness, its use in special populations, and its dissemination in endemic regions. Pending further results from Phase 3 trials, Mosquirix has the potential to become the benchmark as the first vaccine against malaria that is highly effective and safe.
Source...